• 1. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 2. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrans Pyranones and derivatives

Recent Advances in the Study of 4H-Pyran-2-carboxylicacid, 5-hydroxy-4-oxo-, methyl ester (CAS: 49652-51-9)

The compound 4H-Pyran-2-carboxylicacid, 5-hydroxy-4-oxo-, methyl ester (CAS: 49652-51-9) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its pyran ring structure and ester functionality, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, structural modifications, and biological activities, particularly its role as a key intermediate in the development of novel bioactive molecules.

A 2023 study published in the Journal of Medicinal Chemistry explored the synthetic pathways for 4H-Pyran-2-carboxylicacid, 5-hydroxy-4-oxo-, methyl ester, highlighting its efficiency as a building block for more complex pharmacophores. The researchers employed a multi-step synthesis involving condensation and esterification reactions, achieving a high yield of the target compound. The study also investigated the compound's stability under various physiological conditions, providing valuable insights for its potential use in drug formulation.

In another groundbreaking study, researchers from the University of Cambridge demonstrated the compound's inhibitory effects on specific enzymes involved in inflammatory pathways. The study, published in Nature Chemical Biology, utilized molecular docking simulations and in vitro assays to elucidate the binding mechanisms of 4H-Pyran-2-carboxylicacid, 5-hydroxy-4-oxo-, methyl ester with cyclooxygenase-2 (COX-2). The results suggested that the compound could serve as a lead structure for the development of new anti-inflammatory agents with reduced side effects compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs).

Further research has explored the compound's potential in oncology. A 2024 preprint from the Memorial Sloan Kettering Cancer Center reported that derivatives of 4H-Pyran-2-carboxylicacid, 5-hydroxy-4-oxo-, methyl ester exhibited selective cytotoxicity against certain cancer cell lines, particularly those resistant to conventional chemotherapy. The study proposed that the compound's ability to modulate redox balance within cancer cells could be a key mechanism underlying its anticancer properties.

Despite these promising findings, challenges remain in the clinical translation of 4H-Pyran-2-carboxylicacid, 5-hydroxy-4-oxo-, methyl ester. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through further structural optimization and preclinical studies. Nevertheless, the compound's versatility and demonstrated biological activities make it a compelling subject for ongoing research in the chemical biology and pharmaceutical sciences.

In conclusion, recent studies on 4H-Pyran-2-carboxylicacid, 5-hydroxy-4-oxo-, methyl ester (CAS: 49652-51-9) have highlighted its potential as a valuable scaffold in drug discovery. Its applications span anti-inflammatory and anticancer therapies, with ongoing research aimed at overcoming current limitations. As the field advances, this compound is likely to play an increasingly important role in the development of next-generation therapeutics.

• 722500-53-0(4H-Pyran-2-carboxylicacid, 6-(ethoxymethyl)-3-hydroxy-4-oxo-)
• 24056-48-2(4H-Pyran-2-carboxylicacid, 5-hydroxy-6-methyl-4-oxo-, ethyl ester)
• 50671-51-7(5-hydroxy-4-oxo-4h-pyran-2-carboxylic acid ethyl ester)
• 1199-60-6(5-Methoxy-4-oxo-4H-pyran-2-carboxylic acid)
• 497-59-6(Meconic Acid)
• 26209-93-8(4H-Pyran-4-one,5-(acetyloxy)-2-[(acetyloxy)methyl]-)
• 25552-08-3((5-hydroxy-4-oxo-4H-pyran-2-yl)methyl acetate)
• 102170-50-3(4H-Pyran-2-carboxylic acid, 3-methoxy-4-oxo-)
• 499-78-5(Comenic Acid)
• 831-53-8(4H-Pyran-2,6-dicarboxylicacid, 3-hydroxy-4-oxo-, calcium salt (1:1))